E-Mail
PITTSBURGH, 9 March 2021 - If approved, the monthly dapivirine vaginal ring would be the first biomedical HIV prevention method designed specifically for cisgender women, as well as the first long-acting method. Looking to the future, researchers from the National Institutes of Health-funded Microbicide Trials Network are hopeful that a vaginal ring that could be used for longer than a month at a time might also be made available someday.
Indeed, a 90-day dapivirine ring has passed its first test, with results of a Phase I clinical trial reported today at a virtual meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) supporting its further development.
Mutation detectives: How new COVID-19 variants are known, meet some of the people who assiduously track them gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.
Alerts A health worker at the Wits Reproductive Health and HIV Institute (WRHI) in Johannesburg, South Africa showing off a Dapivirine vaginal ring that would be used in an HIV prevention trial on July 20, 2012
Photo: Stephane De Sakutin/AFP (Getty Images)
The next generation of medications and preventative treatments for HIV/AIDS continues to look promising. New research released Tuesday suggests that people can safely wear a vaginal ring-based treatment meant to prevent HIV infection for as long as three months. A monthly version of the same drug is already being weighed for approval in African countries and elsewhere.
Advertisement
COVID-19 in Wisconsin: 29 new deaths, 463 new cases kstp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kstp.com Daily Mail and Mail on Sunday newspapers.